- Home
- ATCH vs CYCC Comparison
ATCH vs CYCC Comparison
Compare ATCH & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- CYCC
- Stock Information
- Founded
- ATCH 2022
- CYCC 1992
- Country
- ATCH United States
- CYCC United States
- Employees
- ATCH N/A
- CYCC N/A
- Industry
- ATCH
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- CYCC Health Care
- Exchange
- ATCH Nasdaq
- CYCC Nasdaq
- Market Cap
- ATCH 4.4M
- CYCC 3.6M
- IPO Year
- ATCH N/A
- CYCC N/A
- Fundamental
- Price
- ATCH $0.54
- CYCC $0.23
- Analyst Decision
- ATCH
- CYCC Strong Buy
- Analyst Count
- ATCH 0
- CYCC 1
- Target Price
- ATCH N/A
- CYCC $11.00
- AVG Volume (30 Days)
- ATCH 2.1M
- CYCC 161.7K
- Earning Date
- ATCH 05-27-2025
- CYCC 05-13-2025
- Dividend Yield
- ATCH N/A
- CYCC N/A
- EPS Growth
- ATCH N/A
- CYCC N/A
- EPS
- ATCH 2.67
- CYCC N/A
- Revenue
- ATCH N/A
- CYCC $43,000.00
- Revenue This Year
- ATCH N/A
- CYCC N/A
- Revenue Next Year
- ATCH N/A
- CYCC $88.68
- P/E Ratio
- ATCH $0.21
- CYCC N/A
- Revenue Growth
- ATCH N/A
- CYCC N/A
- 52 Week Low
- ATCH $0.49
- CYCC $0.22
- 52 Week High
- ATCH $99.00
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- ATCH 28.09
- CYCC 26.52
- Support Level
- ATCH $0.87
- CYCC $0.22
- Resistance Level
- ATCH $1.10
- CYCC $0.32
- Average True Range (ATR)
- ATCH 0.10
- CYCC 0.02
- MACD
- ATCH 0.08
- CYCC -0.01
- Stochastic Oscillator
- ATCH 6.92
- CYCC 9.09
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.